Former Chief Executive Officer, Chairman (3) · Virpax Pharmaceuticals, Inc. (VRPX)

Anthony Mack

A named executive officer of Virpax Pharmaceuticals in every fiscal year CompBrief holds from FY2022 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,216,000

Salary $445,000Stock awards $0

FY2022: $784,000

1st of 5 named executive officers at Virpax Pharmaceuticals by FY2023 total.

5 named officers on file for Virpax Pharmaceuticals, FY2023

Anthony Mack’s pay file — $29

  • 2 fiscal years of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Virpax Pharmaceuticals’s whole pay program stands against its peers

  • Virpax Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRPX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed June 12, 2024 (10-K).

Free

Get Anthony Mack’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anthony Mack compensation by year

Virpax Pharmaceuticals Summary Compensation Table · all 2 fiscal years held
In US dollars, as Virpax Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2022FY2023
Salary$467,000$445,000
Bonus$238,000$0
Stock awards$0$0
Option awards$79,000$60,000
Non-equity incentive$0$0
Pension and deferred compensation$0$0
All other$0$711,000
Total$784,000$1,216,000

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Virpax Pharmaceuticals, Inc. 10-K filed June 12, 2024, accession 0001213900-24-052146, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Virpax Pharmaceuticals, Inc. filed document, accession 0001213900-24-052146. Every figure is read from that document and cited to the page and table it appears in. Filed June 12, 2024.

$784K
$1.2M
FY22
FY23
SalaryBonusOption awardsAll other

Virpax Pharmaceuticals’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Anthony Mack · this pageFormer Chief Executive Officer, Chairman (3)$1,216,000
Sheila MathiasChief Scientific Officer$498,000
Christopher ChipmanFormer Chief Financial Officer (5)$491,000
Vinay ShahChief Financial Officer$324,000
Gerald BruceChief Executive Officer$128,000

The full Virpax Pharmaceuticals compensation record

free company brief

This page is one person within Virpax Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Virpax Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anthony Mack's compensation dossier · One-time report. No refunds.